InvestorsHub Logo
Followers 23
Posts 1671
Boards Moderated 0
Alias Born 09/04/2009

Re: None

Monday, 03/28/2016 9:05:14 AM

Monday, March 28, 2016 9:05:14 AM

Post# of 42816
Durrant expects the additional liquidity to allow the company to begin the revival of its drug development programs, as well as begin a clinical testing program for KB003, a drug used to treat chronic myelomonocytic leukemia, or CMML. The DIP Financing has potential to send a very positive signal to the marketplace that KaloBios is making progress and will soon exit bankruptcy.

http://seekingalpha.com/article/3961284-comeback-kalobios